Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company has operations in pharmaceutical, animal health, and consumer care.
Website: merck.com


  • Pretty weak financial results growth rate 1.8% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (14.2%)
  • Dividend yield for the last twelve months 4.1%
  • Free cash flow yield 1.5% (LTM)
  • Share price is 6.1% higher than minimum and 41.4% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (9.0x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $0.4 mln (0.000% of cap.)

Key Financials (Download financials)

Ticker: MRK
Share price, USD:  (-0.4%)77.96
year average price 102.07  


year start price 130.52 2024-06-06

max close price 132.96 2024-06-24

min close price 73.47 2025-05-14

current price 77.92 2025-06-05
Common stocks: 2 528 810 012

Dividend Yield:  4.1%
FCF Yield LTM: 1.5%
EV / LTM EBITDA: 9.0x
EV / EBITDA annualized: 8.0x
Last revenue growth (y/y):  -1.6%
Last growth of EBITDA (y/y):  +5.2%
Historical revenue growth:  +6.4%
Historical growth of EBITDA:  +22.0%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 197 146
Net Debt ($m): 25 681
EV (Enterprise Value): 222 827
EBITDA LTM ($m): 24 783
EV / LTM EBITDA: 9.0x
Price to Book: 4.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-05-31businesswire.com

KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)

2025-05-30businesswire.com

Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations

2025-05-29seekingalpha.com

Merck & Co., Inc. (MRK) Bernstein 41st Annual Strategic Decisions Conference (Transcript)

2025-05-27seekingalpha.com

Merck Proves Why It's Still A Top Pharma Pick

2025-05-27businesswire.com

Merck Announces Third-Quarter 2025 Dividend

2025-05-26zacks.com

MRK Down 21% YTD: Should You Buy, Hold or Sell the Stock?

2025-05-26forbes.com

Should You Buy MRK Stock At $80?

2025-05-23seekingalpha.com

Merck: Defensive Yield Meets Long-Term Optionality

2025-05-22businesswire.com

Merck Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 2025

2025-05-22businesswire.com

Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data